Objetivo: testar las muestras del estudio “Efficacy and neurological adverse effects of COVID-19 vaccination in patients
immunocompromised for multiple sclerosis”
Muestras: (22 muestras del estudio EM vacunas de H.Santpau, Cpos y Cneg)
| 1 | 98722 | T3 |
| 2 | 111955 | T3 |
| 3 | 147303 | T3 |
| 4 | 190943 | T3 |
| 5 | 219804 | T3 |
| 6 | 266178 | T3 |
| 7 | 304320 | T3 |
| 8 | 344185 | T3 |
| 9 | 422044 | T3 |
| 10 | 461265 | T3 |
| 11 | 472720 | T3 |
| 12 | 493713 | T3 |
| 13 | 505343 | T3 |
| 14 | 591615 | T3 |
| 15 | 597217 | T3 |
| 16 | 631193 | T3 |
| 17 | 814329 | T3 |
| 18 | 901936 | T3 |
| 19 | 927164 | T3 |
| 20 | 950931 | T3 |
| 21 | 1004410 | T3 |
| 22 | 1021881 | T3 |
Protocolo:
- Bloquear con leche 5% en PBS-tween 0’1% : 200 ul pozo (incubar 1h a temp. ambiente)
- Lavar 3 veces con PBS-tween 0’1%
- Diluir los sueros:
- Screening: diluir sueros 1/100 en leche 5% en PBS-tween 0’1%
- Incubar con los sueros 1h
- Lavar 3 veces con PBS-tween 0’1%
- Incubar 45min con RAH IgG HRP 1/3000 en leche 5% en PBS-tween 0’1% : 100 ul/pozo
- Lavar 3 veces con PBS-tween 0’1%
- Incubar 5min con TMB: preparar solución un rato antes y tapar de la luz (para que se atempere) : 100 ul/pozo
- Parar la reacción con 50ul de H2SO4 25%
- Leer a 450-620 nm
| Placa 1 | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| A prot | Cneg | 3 | 7 | 11 | 15 | 19 | Cneg | 3 | 7 | 11 | 15 | 19 |
| Bblanc | Cneg | 3 | 7 | 11 | 15 | 19 | Cneg | 3 | 7 | 11 | 15 | 19 |
| C prot | Cpos | 4 | 8 | 12 | 16 | 20 | Cpos | 4 | 8 | 12 | 16 | 20 |
| Dblanc | Cpos | 4 | 8 | 12 | 16 | 20 | Cpos | 4 | 8 | 12 | 16 | 20 |
| E prot | 1 | 5 | 9 | 13 | 17 | 21 | 1 | 5 | 9 | 13 | 17 | 21 |
| F blanc | 1 | 5 | 9 | 13 | 17 | 21 | 1 | 5 | 9 | 13 | 17 | 21 |
| G prot | 2 | 6 | 10 | 14 | 18 | 22 | 2 | 6 | 10 | 14 | 18 | 22 |
| Hblanc | 2 | 6 | 10 | 14 | 18 | 22 | 2 | 6 | 10 | 14 | 18 | 22 |
